Processing

Please wait...

Settings

Settings

Goto Application

1. WO2000034243 - N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS

Publication Number WO/2000/034243
Publication Date 15.06.2000
International Application No. PCT/GB1999/004118
International Filing Date 06.12.1999
Chapter 2 Demand Filed 08.06.2000
IPC
C07D 211/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
211Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
04with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
06having no double bonds between ring members or between ring members and non-ring members
08with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
18with substituted hydrocarbon radicals attached to ring carbon atoms
20with hydrocarbon radicals, substituted by singly bound oxygen or sulfur atoms
24by sulfur atoms to which a second hetero atom is attached
C07D 401/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
401Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
CPC
A61P 1/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
08for nausea, cinetosis or vertigo; Antiemetics
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 13/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
02of urine or of the urinary tract, e.g. urine acidifiers
A61P 25/22
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
22Anxiolytics
A61P 25/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
24Antidepressants
A61P 43/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applicants
  • ASTRAZENECA AB [SE]/[SE] (AllExceptUS)
  • OHNMACHT, Cyrus, John [US]/[US] (UsOnly)
Inventors
  • OHNMACHT, Cyrus, John
Agents
  • DENERLEY, Paul, Millington
Priority Data
9826941.809.12.1998GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS
(FR) N-(2-PHENYLE-4-PIPERIDINYBUTYLE)-5,6,7,8-TETRAHYDRO-1-NAPTHALENE CARBOXAMIDES ET LEUR UTILISATION COMME ANTAGONISTES DES RECEPTEURS DE LA NEUROKININE 1 (NK1) ET/OU DE LA NEUROKININE 2 (NK2)
Abstract
(EN)
Compounds of formula (I), wherein R2 is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.
(FR)
Cette invention concerne des composés représentées par la formule (I), dans laquelle R2 est un groupe 5,6,7,8-tétrahydronaphth-1-yl qui peut être substitué (par les groupes restants définis ici), et des compositions pharmaceutiques renfermant ces composés. L'invention concerne également des méthodes d'utilisation de ces composés pour le traitement de pathologies dans lesquelles l'antagonisme des récepteurs de NK1 et/ou de NK2 est bénéfique.
Latest bibliographic data on file with the International Bureau